Answers to common questions about PExpo and UK telehealth

PExpo is a UK telehealth platform operated by Pharmaexpo Ltd that provides dispensing infrastructure and white-label online clinics services for clinics and brands. Two operating models: a clinic model with £0 platform fees and per-request pricing, and a brand model with white-label integrated clinical workflow, UK prescriber network, and GPhC-compliant dispensing.

The clinic model has £0 platform fees with a transparent admin client care fee per request. The brand model is per-dispense pricing configured per-category, discussed on a discovery call. Full commercial detail on the pricing page.

Typically 3 to 6 weeks from signed contract to first patient, meaningfully faster than the 12–18 months a build-from-scratch route would require, because clinical workflow, UK prescribers, and dispensing are pre-integrated.

Yes. PExpo's dispensing operation handles controlled drug supply under UK regulatory frameworks with the required additional controls (identity verification, defined quantities, robust pharmacovigilance, shared-care arrangements where applicable).

Yes. PExpo dispenses cold-chain medicines under UK Good Distribution Practice with validated packaging, monitored temperature chain, and appropriate courier arrangements. Handles both injectable and (as of 2026) oral GLP-1 formats.

Five key regulators. GPhC: pharmacies, pharmacists, and pharmacy technicians (dispensing). MHRA: medicines licensing, advertising, pharmacovigilance. CQC: clinical services in England (Scotland, Wales, Northern Ireland have separate regulators). ICO: data protection (UK GDPR). ASA: advertising via the CAP Code.

In England, yes, for any service involving clinical consultation, diagnosis, or treatment. Application takes 10–14 weeks. Scotland, Wales, and Northern Ireland have separate equivalent regulators.

No. Prescription-only medicines cannot be advertised to the public under the Human Medicines Regulations 2012. Applies to injectable and oral formats. Marketing the clinical service is legitimate; marketing the medicine by name is not.

The MHRA system for reporting suspected adverse drug reactions in the UK. UK telehealth operators dispensing licensed medicines are expected to submit reports for suspected reactions identified through clinical assessment. Under-reporting is a consistent MHRA enforcement theme.

Yes, by partnering with a GPhC-registered pharmacy that handles the dispensing. Your brand or clinic operates patient-facing; the partner pharmacy handles the regulated dispensing activity. This is exactly what PExpo enables.

Yes. The clinic model is built specifically for existing UK clinics (private GPs, specialist clinics, dental, aesthetic) adding online prescribing without building their own pharmacy. £0 platform fees, transparent per-request pricing, same-day dispatch on in-stock SKUs.

Yes. The brand model is the white-label option for founders launching new UK telehealth brands. Integrated clinical workflow, UK prescriber network (medical doctors and pharmacist independent prescribers), GPhC-compliant dispensing, pharmacovigilance, and supporting integrations.

REST API + signed webhooks. Native integrations with Stripe, Adyen, Onfido, Veriff, Yoti, Intercom, Zendesk, Customer.io, Segment, Slack, Cal.com, JotForm, PostHog, Amplitude, and more. See the integrations page for the full list.

Yes, but the regulated activities (dispensing, prescribing) must be performed by UK-registered entities and clinicians, and the company structure typically requires UK substance for CQC registration and tax purposes. Overseas founders typically operate via a UK-incorporated company using the white-label partnership route.

Four revenue streams: margin on prescription medicines (typically 20–50%), dispensing fees per item (£4–£15 typical), consultation fees where unbundled (£15–£75), and OTC / adjacent products. Profit depends on whether lifetime patient value exceeds acquisition cost.

£200,000–£500,000+ per year for a small-to-medium operation covering premises, superintendent pharmacist, baseline staff, technology, supplies, insurance, and compliance. The fixed-cost floor doesn't scale down, which is why partnering usually beats building below ~8,000–10,000 monthly dispenses.

£80,000–£250,000 via a white-label partnership route (PExpo brand model), or £600,000–£1.5m+ if building the pharmacy and clinical workflow in-house. Most 2026 launches partner; build economics only justify at higher scale.

Multi-platform research: Google and AI search (ChatGPT, Perplexity, Claude, Google AI Overviews). They comparison-shop across 2–4 operators. They scrutinise clinical credentials, community sentiment (Reddit, forums), and pricing transparency. Substance wins over polish.

Yes. H1 2026 confirmed AI search as a meaningful patient research channel. The retrofit is largely structural (question H1s, FAQPage / QAPage schema, Speakable markup) rather than new content. The competitive window is still open through H2 2026.